METiS TechBio, a Chinese biotech company, made history by becoming the world's first publicly listed AI-powered drug delivery company when it debuted on the Hong Kong Stock Exchange in May 2026, raising over HKD 2.1 billion (approximately $265 million USD) and attracting major institutional investors including BlackRock. The company's achievement marks a significant milestone in how artificial intelligence is reshaping pharmaceutical development, moving beyond protein prediction into the practical challenge of getting drugs to the right place in the human body.

The IPO generated extraordinary investor demand, with the Hong Kong public offering oversubscribed more than 6,900 times and locking up over HKD 730 billion in subscription funds. The international placing attracted orders from more than 280 institutional investors with 82 times oversubscription. A total of 18 cornerstone investors committed USD 148 million, with BlackRock leading the charge at USD 50 million.

What Makes METiS TechBio's AI Platform Different?

At the heart of METiS TechBio's competitive advantage is NanoForge, a proprietary AI platform designed specifically for drug delivery challenges. Unlike general-purpose AI tools, NanoForge combines multiple specialized technologies to solve a problem that has plagued pharmaceutical development for decades: how to deliver drugs precisely to diseased cells while minimizing side effects.

The platform's capabilities include:

• Ionizable Lipid Library: The company has built the world's largest library of ionizable lipids at the scale of tens of millions, which are fatty molecules that help transport drugs through the body
• De Novo Lipid Generation: METiS developed the world's only algorithm for creating entirely new lipid molecules from scratch, plus a lipid language model that understands how different molecular structures behave
• Screening Platform: The company established the world's first end-to-end lipid and lipid nanoparticle (LNP) screening platform, which tests thousands of delivery combinations automatically
• Multiscale Simulation: METiS created the world's first AI-powered multiscale simulation platform for small-molecule formulation development, allowing researchers to predict how drugs will behave before physical testing

These tools work together to address a fundamental bottleneck in drug development. Traditionally, formulating a drug for delivery takes one to two years of preclinical work. Using AiTEM, one of its three core technology solutions, METiS reduced this timeline to less than three months.

How Is METiS Using AI to Target Specific Organs?

One of METiS TechBio's most significant achievements is precision organ targeting. The company has taken the lead in the industry by achieving targeted delivery to eight key organs and tissues: the liver, lungs, heart, muscles, tumor tissues, immune system, central nervous system, and gastrointestinal tract. This capability opens the door to treating diseases that have been difficult to address because existing drugs cannot reach the affected tissue safely.

A concrete example is MTS-004, which the company describes as China's first AI-enabled formulation drug to complete Phase III clinical trials. This medication treats pseudobulbar affect (PBA), a condition involving involuntary emotional outbursts. The entire development timeline from project initiation to completion of Phase III trials took 38 months, a dramatic acceleration compared to traditional timelines.

Another pipeline product, MTS-105, represents an even more ambitious application. It is designed to be the world's first in vivo mRNA-encoded TCE (T-cell engager) therapy for solid tumors, specifically targeting liver cancer and advanced solid tumors with liver metastases. By using METiS's AiLNP and AiRNA platforms, the drug enables highly efficient expression of therapeutic proteins directly in cancer cells, activating the immune system to attack tumors. MTS-105 has already received Orphan Drug Designation from the U.S. FDA.

Steps to Understanding How AI Drug Delivery Works in Practice

• Step 1: Design the Delivery Vehicle: AI algorithms generate millions of potential lipid molecules and test their properties computationally, selecting the most promising candidates for physical testing
• Step 2: Screen Combinations: High-throughput screening platforms automatically test thousands of lipid combinations to find the optimal formulation for each drug and target tissue
• Step 3: Simulate Real-World Behavior: Quantum chemistry and molecular dynamics simulations predict how the drug will behave inside the human body before clinical trials begin
• Step 4: Accelerate Clinical Development: By reducing preclinical timelines from years to months, companies can move promising candidates into human testing faster, potentially bringing treatments to patients years earlier

The practical impact is substantial. METiS's pipeline includes more than 10 drug candidates at various stages of development, including four preclinical candidates, three clinical-stage products, and one pre-NDA (New Drug Application) product. The company has filed 224 patent applications and been granted 52 patents, protecting its technological innovations.

Why Are Major Investors Betting Big on AI Drug Delivery?

The investor response to METiS's IPO signals a broader recognition that AI-powered drug delivery represents a critical technology for the future of biopharmaceuticals. The cornerstone investor list reads like a who's who of global finance and specialized healthcare investment: UBS Asset Management Singapore, Mirae Asset of South Korea, ORIX Corporation of Japan, Deerfield, RTW, Lake Bleu Capital, Walden International, Hillhouse Capital, and IDG Capital all participated.

Notably, Guofengtou Innovation Investment Fund, a state-level Chinese fund, made its first investment in the AI pharmaceutical sector by backing METiS. This signals that AI drug delivery has risen to the level of a national strategic priority in China. The involvement of top Chinese public fund managers including GF Fund, ICBC UBS Asset Management, China Asset Management, and Fullgoal Fund, all making rare joint appearances as subscribers with lock-up commitments, further underscores the strategic importance of this technology.

"The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells," stated Dr. Chris Lai, Co-Founder, Chairman and Chief Executive Officer of METiS TechBio.

Dr. Chris Lai, Co-Founder, Chairman and Chief Executive Officer of METiS TechBio

The IPO represents more than just a financial milestone. It demonstrates that AI-powered drug delivery has moved from academic research and private funding into the public markets, where it can attract sustained capital and scrutiny. For patients, this means that treatments currently in development could reach the market years faster than traditional approaches would allow. For the pharmaceutical industry, it signals that companies investing in AI-powered formulation and delivery technologies may gain significant competitive advantages in bringing new drugs to market.